Literature DB >> 20833377

In vivo mechanisms of vaccine-induced protection against HPV infection.

Patricia M Day1, Rhonda C Kines, Cynthia D Thompson, Subhashini Jagu, Richard B Roden, Douglas R Lowy, John T Schiller.   

Abstract

Using a human papillomavirus (HPV) cervicovaginal murine challenge model, we microscopically examined the in vivo mechanisms of L1 virus-like particle (VLP) and L2 vaccine-induced inhibition of infection. In vivo HPV infection requires an initial association with the acellular basement membrane (BM) to induce conformational changes in the virion that permit its association with the keratinocyte cell surface. By passive transfer of immune serum, we determined that anti-L1 antibodies can interfere with infection at two stages. Similarly to active VLP immunization, transfer of high L1 antibody concentrations prevented BM binding. However, in the presence of low concentrations of anti-L1, virions associated with the BM, but to the epithelial cell surface was not detected. Regardless of the concentration, L2 vaccine-induced antibodies allow BM association but prevent association with the cell surface. Thus, we have revealed distinct mechanisms of vaccine-induced inhibition of virus infection in vivo.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20833377      PMCID: PMC2939057          DOI: 10.1016/j.chom.2010.08.003

Source DB:  PubMed          Journal:  Cell Host Microbe        ISSN: 1931-3128            Impact factor:   21.023


  43 in total

1.  Nuclear translocation of papillomavirus minor capsid protein L2 requires Hsc70.

Authors:  Luise Florin; Katrin A Becker; Cornelia Sapp; Carsten Lambert; Hüseyin Sirma; Martin Müller; Rolf E Streeck; Martin Sapp
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

2.  Immunological analyses of human papillomavirus capsids.

Authors:  T Giroglou; M Sapp; C Lane; C Fligge; N D Christensen; R E Streeck; R C Rose
Journal:  Vaccine       Date:  2001-02-08       Impact factor: 3.641

3.  Alteration of virus entry mode: a neutralisation mechanism for Dengue-2 virus.

Authors:  S Y Se-Thoe; A E Ling; M M Ng
Journal:  J Med Virol       Date:  2000-11       Impact factor: 2.327

4.  Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.

Authors:  R B Roden; W H Yutzy; R Fallon; S Inglis; D R Lowy; J T Schiller
Journal:  Virology       Date:  2000-05-10       Impact factor: 3.616

5.  Antibody-mediated neutralization in vivo of infectious papillomaviruses.

Authors:  N D Christensen; J W Kreider
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

6.  Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression.

Authors:  Patricia M Day; Carl C Baker; Douglas R Lowy; John T Schiller
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-21       Impact factor: 11.205

7.  Against which human papillomavirus types shall we vaccinate and screen? The international perspective.

Authors:  Nubia Muñoz; F Xavier Bosch; Xavier Castellsagué; Mireia Díaz; Silvia de Sanjose; Doudja Hammouda; Keerti V Shah; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2004-08-20       Impact factor: 7.396

8.  Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

Authors:  Diana V Pastrana; Christopher B Buck; Yuk-Ying S Pang; Cynthia D Thompson; Philip E Castle; Peter C FitzGerald; Susanne Krüger Kjaer; Douglas R Lowy; John T Schiller
Journal:  Virology       Date:  2004-04-10       Impact factor: 3.616

Review 9.  Classification of papillomaviruses.

Authors:  Ethel-Michele de Villiers; Claude Fauquet; Thomas R Broker; Hans-Ulrich Bernard; Harald zur Hausen
Journal:  Virology       Date:  2004-06-20       Impact factor: 3.616

10.  Distinctive populations of basement membrane and cell membrane heparan sulfate proteoglycans are produced by cultured cell lines.

Authors:  J L Stow; M G Farquhar
Journal:  J Cell Biol       Date:  1987-07       Impact factor: 10.539

View more
  79 in total

1.  Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years).

Authors:  Fangjian Guo; Jacqueline M Hirth; Abbey B Berenson
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions.

Authors:  Douglas R Lowy
Journal:  J Clin Invest       Date:  2016-01-04       Impact factor: 14.808

Review 3.  Prevention of cancer by prophylactic human papillomavirus vaccines.

Authors:  Kihyuck Kwak; Anna Yemelyanova; Richard B S Roden
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

4.  A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.

Authors:  Patricia M Day; Yuk-Ying S Pang; Rhonda C Kines; Cynthia D Thompson; Douglas R Lowy; John T Schiller
Journal:  Clin Vaccine Immunol       Date:  2012-05-16

Review 5.  Progress and prospects for L2-based human papillomavirus vaccines.

Authors:  Rosie T Jiang; Christina Schellenbacher; Bryce Chackerian; Richard B S Roden
Journal:  Expert Rev Vaccines       Date:  2016-03-10       Impact factor: 5.217

6.  Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years.

Authors:  Tino F Schwarz; Marek Spaczynski; Achim Schneider; Jacek Wysocki; Andrzej Galaj; Karin Schulze; Sylviane M Poncelet; Gregory Catteau; Florence Thomas; Dominique Descamps
Journal:  Hum Vaccin       Date:  2011-09-01

Review 7.  Concepts of papillomavirus entry into host cells.

Authors:  Patricia M Day; Mario Schelhaas
Journal:  Curr Opin Virol       Date:  2013-12-14       Impact factor: 7.090

8.  Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.

Authors:  Subhashini Jagu; Kihyuck Kwak; John T Schiller; Douglas R Lowy; Harold Kleanthous; Kirill Kalnin; Chenguang Wang; Hsu-Kun Wang; Louise T Chow; Warner K Huh; Kilvani S Jaganathan; Sudha V Chivukula; Richard B S Roden
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

9.  Human papilloma virus vaccination in patients with an aggressive course of recurrent respiratory papillomatosis.

Authors:  Irena Hočevar-Boltežar; Mojca Matičič; Maja Sereg-Bahar; Nina Gale; Mario Poljak; Boštjan Kocjan; Miha Zargi
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-06-26       Impact factor: 2.503

10.  Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.

Authors:  Mitchell Tyler; Ebenezer Tumban; Agnieszka Dziduszko; Michelle A Ozbun; David S Peabody; Bryce Chackerian
Journal:  Vaccine       Date:  2014-06-21       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.